FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma |
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma. |
Read more
|
|
ICYMI: Young Adults with CRC in Low Income and Education Populations More Likely to Have Worse OS |
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities. |
Read more
|